Maxim starts Autonomix with Buy on platform technology

Maxim initiated coverage of Autonomix (AMIX) with a Buy rating and $5 price target The company’s platform technology could transform the field of electrophysiology by detecting neural signals that indicate pain or disease and destroying those nerves at the source, the analyst tells investors in a research note. The firm says that while the initial focus is on pancreatic cancer pain, the technology has the potential to address multiple indications involving the peripheral nervous system, chronic pain management, hypertension, cardiovascular disease, and other tumor-related pain. It believes Autonomix has sufficient capital to operate into Q3 of fiscal 2026.